Fior Markets launched a study titled “Global Hormonal Contraceptive Market by Method (Combined Oral Contraceptives, Oral ContraceptivesImplanted Contraceptives, Injected Contraceptives, Intrauterine, others), Hormones, End-Users, Region” and Global Forecast 2018-2025.

The global hormonal contraceptivemarket is expected to reach USD 19.31 Billion in 2017 to USD 31.07 Billion by 2025 at a CAGR of 5.80%during the forecast periodfrom 2018-2025. Increasing awareness about reproductive and sexual health worldwide and increase in women population around the world are driving the growth of the market.Increasing number of females using contraceptives in emerging economies due to rise in government initiatives and programs are accelerating growth of the market. For instance, as per UN, around 64.0% of women aged between 15 and 49 years were using some form of family planning in 2015, either traditional or modern.


Oral contraceptive segment accounted for the largest market share of 38.94% in 2017

The methodsegment is classified into combined oral, oral contraceptive, implanted, injected, intrauterine, transdermal patch, and vaginal ring contraceptives. Oral contraceptive segment accounted for the largest market share of 38.94% in 2017. Easy mode of administration, wide range of availability and high awareness about pills are driving the growth of the segment.

Hormones segment is divided into androgens, estrogens, progestrogens, gonadotropins, antiandrogens and others. Increase in prevalence of PCOS, fewer side effects and effective resultsthan progestin contraceptives makes other hormones preferred choice.

End user segment is classified intohospitals, homecare, gynecologycenters, clinics and ambulatory surgical centers.


Regional Segmentation Analysis:

The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. NorthAmerica region dominated the marketand held the largest market share of 52.21%in 2017. High income, strong presence of major market players, higher awareness about sexual health and large number of unintended pregnancies are some of the major factors driving the growth of the market in region.Asia pacific is projected to be fastest growing region in the forecast period due to Large fertile population, introduction of new female contraception devices and rise in investment by are the major factors supplementing the growth of the region.

Competitive Analysis:

Major industry players in the market include Teva Pharmaceutical, Amgen, Sun Pharmaceutical, Bayer Healthcare, Piramal Healthcare, Cipla Limited, Pfizer, Inc., Glenmark Pharmaceuticals, Novartis AG, Lupin Pharmaceuticals, Reckitt Benckiser Plc, HLL Lifecare Limited, BoehringerIngelheim GmbH, Watson Pharmaceuticals, Inc., V-Care PharmaPvt. Ltd., Vardhman Life Careand others.Extensive product portfolio and expansion strategies by major players are contributing for the growth of the sector.For instance, in March 2017, TEVA launched generics of Minastrin 24 Fe-ethinylestradiol&norethindrone acetate tablets and ferrous fumarate tablets. These are used as oral contraceptive in the U.S.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team(,who will ensure that you get a report that suits your needs.